Tectonic shifts in the health information economy.

n engl j med 358;16 www.nejm.org april 17, 2008 1732 Wazana A. Physicians and the pharmaceutical industry: is a gift ever just a gift? JAMA 2000;283:373-80. Peay MY, Peay ER. Innovation in high risk drug therapy. Soc Sci Med 1994;39:39-52. Monane M, Glynn RJ, Gurwitz JH, Bohn RL, Levin R, Avorn J. Trends in medication choices for hypertension in the elderly: the decline of the thiazides. Hypertension 1995;25:1045-51. Fischer MA, Avorn J. Economic implications of evidencebased prescribing for hypertension: can better care cost less? JAMA 2004;291:1850-6. Steinman MA, Harper GM, Chren M-M, Landefeld CS, Bero LA. Characteristics and impact of drug detailing for gabapentin. PLoS Med 2007;4(4):e134. Berenson A. Jury finds Merck liable in Vioxx death and awards $253 million. New York Times. August 19, 2005. Topol EJ. Nesiritide — not verified. N Engl J Med 2005; 353:113-6. Kesselheim AS, Fischer MA, Avorn J. The rise and fall of Natrecor for congestive heart failure: implications for drug policy. Health Aff (Millwood) 2006;25:1095-102. Tabarrok AT. Assessing the FDA via the anomaly of off-label drug prescribing. Independent Review 2000;V(1):25-53. Radley DC, Finkelstein SN, Stafford RS. Off-label prescribing among office-based physicians. Arch Intern Med 2006;166: 1021-6. Alexopoulos GS, Streim J, Carpenter D, Docherty JP. Using 25.